目的 研究三七通舒胶囊联合单唾液酸四己糖神经节苷脂钠注射液治疗急性脑梗死的临床疗效。方法 选取2016年8月-2018年8月延安大学咸阳医院收治的85例急性脑梗死患者为研究对象，将所有患者随机分为对照组（42例）和治疗组（43例）。对照组患者静脉滴注单唾液酸四己糖神经节苷脂钠注射液，40 mg加入到0.9%氯化钠注射液250 mL中，1次/d；治疗组在对照组基础上口服三七通舒胶囊，1粒/次，3次/d。两组患者持续治疗4周。观察两组的临床疗效，比较两组的美国国立卫生研究院卒中量表（NHISS）评分，以及丙二醛（MDA）、神经元特异性烯醇化酶（NSE）、肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）、脑源性神经营养因子（BDNF）和谷胱甘肽过氧化物酶（GSH-Px）水平。结果 治疗后，对照组和治疗组的总有效率分别为83.33%、95.35%，两组比较差异有统计学意义（P<0.05）。治疗后，两组MDA、NSE、TNF-α、IL-6水平均显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；并且治疗组MDA、NSE、TNF-α、IL-6水平明显低于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者NIHSS评分显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；并且治疗组患者NIHSS评分明显低于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者BDNF和GSH-Px水平均显著升高，同组治疗前后比较差异有统计学意义（P<0.05）；并且治疗组患者BDNF和GSH-Px水平明显高于对照组，两组比较差异有统计学意义（P<0.05）。结论 三七通舒胶囊联合单唾液酸四己糖神经节苷脂钠注射液治疗急性脑梗死具有较好的临床疗效，能改善神经功能缺损情况，调节MDA、NSE、TNF-α、IL-6、BDNF和GSH-Px水平，具有一定的临床推广应用价值。

Objective To study the effect of Sanqi Tongshu Capsules combined with Monosialotetrahexosylganglioside Sodium for injection in treatment of acute cerebral infarction. Methods Patients (85 cases) with cerebral infarction in Xianyang Hospital of Yan'an University from August 2016 to August 2018 were randomly divided into the control group (42 cases) and the treatment group (43 cases). Patients in the control group were iv administered with Monosialotetrahexosylganglioside Sodium for injection, 40 mg added into normal saline 250 mL, once daily. Patients in the treatment group were po administered with Sanqi Tongshu Capsules on the basis of the control group, 1 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and NIHSS scores, and the levels of MDA, NSE, TNF-α, IL-6, BDNF, and GSH-Px in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 83.33% and 95.35%, respectively, and there was difference between two groups (P<0.05). After treatment, the levels of MDA, NSE, TNF-α, and IL-6 in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, NIHSS scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the NIHSS score in the treatment group was significantly lower than that in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of BDNF and GSH-Px in two groups were significantly increased, and the difference were statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). Conclusion Sanqi Tongshu Capsules combined with Monosialotetrahexosylganglioside Sodium for injection has clinical curative effect in treatment of acute cerebral infarction, can improve the condition of neurological deficit, and regulate the levels of MDA, NSE, TNF-α, IL-6, BDNF, and GSH-px, which has a certain clinical application value.